Researchers at the University of California San Diego have developed a battery-free wearable patch that continuously monitors levodopa levels in people with Parkinson's disease using sweat collected from the fingertip. The soft sensor is designed to provide real-time information about medication levels without requiring blood draws or external power sources, potentially giving clinicians and patients a more accurate way to manage treatment. The technology was described in a study published in the Proceedings of the National Academy of Sciences (PNAS).
The fingertip patch uses an absorbent hydrogel containing salts and biocompatible solvents to draw sweat naturally from the fingertip through osmotic pressure, eliminating the need for exercise or heat to stimulate perspiration. Enzymes embedded within the device react with levodopa present in the sweat, generating a small electrical current that both powers the sensor and measures drug concentration. According to the researchers, the readings closely matched laboratory blood test results, demonstrating the potential for reliable, non-invasive monitoring of Parkinson's medication levels.
Clinical testing also revealed that people with Parkinson's disease clear levodopa from their bodies significantly faster than healthy individuals, helping explain why many patients experience sudden fluctuations in symptom control between medication doses. Because levodopa has a narrow therapeutic window, even relatively small changes in drug levels can lead to periods of severe immobility or involuntary movements. Continuous monitoring could allow clinicians to better understand these fluctuations and optimize dosing schedules based on objective, real-time data rather than patient diaries or occasional blood tests.
The researchers believe the technology could eventually form part of a closed-loop treatment system in which wearable sensors communicate directly with automated drug delivery devices to adjust medication in real time. While additional development and clinical validation are still needed before commercialization, the work highlights the growing potential of self-powered wearable biosensors to support personalized treatment and remote monitoring for chronic neurological diseases.
Click here to read the original news story.